Sinopia Secures Grant Funding from the National Institute of General Medical Sciences to Advance Proprietary Metabolomics Platform tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
SAN DIEGO (BUSINESS WIRE) Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics identified using its proprietary computational drug discovery platform, announced today that it has selected SB-0110 after extensive preclinical studies as its lead clinical candidate for Parkinson’s disease a.